Gender-related safety and efficacy of cardiac resynchronization therapy

Clinical Cardiology

Volumn 36, Issue 11, 2013, Pages 683-690

  Schuchert, Andreas ^a   Muto, Carmine ^b   Maounis, Themistoklis ^c   Frank, Robert ^d   Ella, Rita Omega ^e   Polauck, Alexander ^f   Padeletti, Luigi ^g  

^a Friedrich Ebert Krankenhaus   (Germany)

^b Ospedale Loreto Mare   (Italy)

^c ONASSIS CARDIAC SURGERY CENTER   (Greece)

^d PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^e St Jude Medical   (Belgium)

^f St Jude Medical   (Germany)

^g UNIVERSITY OF FLORENCE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AGED; ARTICLE; CARDIAC RESYNCHRONIZATION THERAPY; CARDIAC RESYNCHRONIZATION THERAPY DEVICE; CARDIOVASCULAR MORTALITY; CONGESTIVE CARDIOMYOPATHY; DEFIBRILLATOR; ELECTROCARDIOGRAPHY; FEMALE; FOLLOW UP; HEART DEATH; HEART FAILURE; HEART LEFT VENTRICLE ENDDIASTOLIC VOLUME; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; PACEMAKER; QUALITY OF LIFE; SEX DIFFERENCE; SURVIVAL RATE; TREATMENT INDICATION; TREATMENT OUTCOME;

AGED; CARDIAC RESYNCHRONIZATION THERAPY; CHRONIC DISEASE; EUROPE; FEMALE; HEALTH STATUS DISPARITIES; HEALTHCARE DISPARITIES; HEART FAILURE; HUMANS; MALE; MIDDLE AGED; QUALITY OF LIFE; RECOVERY OF FUNCTION; RISK ASSESSMENT; RISK FACTORS; SEX FACTORS; SINGLE-BLIND METHOD; STROKE VOLUME; TIME FACTORS; TREATMENT OUTCOME; VENTRICULAR FUNCTION, LEFT;

EID: 84888015024     PISSN: 01609289     EISSN: 19328737     Source Type: Journal    
DOI: 10.1002/clc.22203     Document Type: Article

References (32)

1. Shekelle PG, Rich MW, Morton SC, et al. Efficacy of angiotensin- converting enzyme inhibitors and beta-blockers in the management of left ventricular systolic dysfunction according to race, gender, and diabetic status: a meta-analysis of major clinical trials. J Am Coll Cardiol. 2003; 41: 1529-1538.
2. Rathore SS, Wang Y, Krumholz HM,. Sex-based differences in the effect of digoxin for the treatment of heart failure. N Engl J Med. 2002; 347: 1403-1411.
3. McMurray JV, Adamopoulos S, Stefan D, et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Eur Heart J. 2012: 33; 1787-1847.
4. Dickstein K, Vardas PE, Auricchio A, et al. 2010 Focused Update of ESC Guidelines on device therapy in heart failure: an update of the 2008 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure and the 2007 ESC Guidelines for cardiac and resynchronization therapy. Developed with the special contribution of the Heart Failure Association and the European Heart Rhythm Association. Europace. 2010; 12: 1526-1536.
5. Peterson PN, Daugherty SL, Wang Y, et al. National Cardiovascular Data Registry. Gender differences in procedure-related adverse events in patients receiving implantable cardioverter-defibrillator therapy. Circulation. 2009; 119: 1078-1084.
6. Bristow MR, Saxon LA, Boehmer J, et al. Comparison of Medical Therapy, Pacing and Defibrillation in Heart Failure (COMPANION) Investigators. Cardiac resynchronization therapy with or without implantable defibrillator in advanced chronic heart failure. N Engl J Med. 2004; 350: 2140-2150.
7. Cleland JG, Daubert JC, Erdmann E, et al. Cardiac Resynchronization-Heart Failure (CARE-HF) Study Investigators. The effect of cardiac resynchronization on morbidity and mortality in heart failure. N Engl J Med. 2005; 352: 1539-1349.
8. Moss AJ, Hall WJ, Cannom DS, et al. Cardiac-resynchronization therapy for the prevention of heart-failure events. N Engl J Med. 2009; 361: 1329-1338.
9. Arshad A, Moss AJ, Foster E, et al. Cardiac resynchronization therapy is more effective in women than in men the MADIT-CRT (Multicenter Automatic Defibrillator Implantation Trial With Cardiac Resynchronization Therapy) trial. J Am Coll Cardiol. 2011; 57: 813-820.
10. Dhruva SS, Redberg RF,. Evaluating sex differences in medical device clinical trials: time for action. JAMA. 2012; 307: 1145-1146.
11. Padeletti L, Muto C, Maounis T, et al. Management of Atrial Fibrillation Suppression in AF-HF Comorbidity Therapy Study Group. Atrial fibrillation in recipients of cardiac resynchronization therapy device: 1-year results of the randomized MASCOT trial. Am Heart J. 2008; 156: 520-526.
12. Mooyaart EA, Marsan NA, van Bommel RJ, et al. Comparison of long-term survival of men versus women with heart failure treated with cardiac resynchronization therapy. Am J Cardiol. 2011; 108: 63-68.
13. Zabarovskaja S, Gadler F, Braunschweig F, et al. Women have better long-term prognosis than men after cardiac resynchronization therapy. Europace. 2012; 14: 1148-1155.
14. Alaeddini J, Wood MA, Amin MS, et al. Gender disparity in the use of cardiac resynchronization therapy in the United States. Pacing Clin Electrophysiol. 2008; 31: 468-472.
15. Levy D, Kenchaiah S, Larson MG, et al. Long-term trends in the incidence of and survival with heart failure. N Engl J Med. 2002; 347: 1397-1402.
16. Goldberg RJ, Spencer FA, Farmer C, et al. Incidence and hospital death rates associated with heart failure: a community-wide perspective. Am J Med. 2005; 118: 728-734.
17. Lansky AJ, Hochman JS, Ward PA, et al. Percutaneous coronary intervention and adjunctive pharmacotherapy in women: a statement for healthcare professionals from the American Heart Association. Circulation. 2005; 111: 940-953.
18. Bleeker GB, Schalij MJ, Boersma E, et al. Does a gender difference in response to cardiac resynchronization therapy exist? Pacing Clin Electrophysiol. 2005; 28: 1271-1275.
19. Zardkoohi O, Nandigam V, Murray L, et al. The impact of age and gender on cardiac resynchronization therapy outcome. Pacing Clin Electrophysiol. 2007; 30: 1344-1348.
20. Leyva F, Foley PW, Chalil S, et al. Female gender is associated with a better outcome after cardiac resynchronization therapy. Pacing Clin Electrophysiol. 2011; 34: 82-88.
21. Xu YZ, Friedman PA, Webster T, et al. Cardiac resynchronization therapy: do women benefit more than men? J Cardiovasc Electrophysiol. 2012; 23: 172-178.
22. Gasparini M, Lunati M, Santini M, et al. on behalf of the Insync/Insync ICD Italian Registry. Long-term survival in patients treated with cardiac resynchronization therapy: a 3-year follow-up study from the InSync/InSync ICD Italian Registry. Pacing Clin Electrophysiol. 2006; 29: S2-S10.
23. Lilli A, Ricciardi G, Porciani MC, et al. Cardiac resynchronization therapy: gender related differences in left ventricular reverse remodeling. Pacing Clin Electrophysiol. 2007; 30: 1349-1355.
24. Tamura T, Said S, Gerdes A,. Gender-related differences in myocyte remodeling in progression to heart failure. Hypertension. 1999; 33: 676-680.
25. Cheng A, Gold MR, Waggoner AD, et al. Potential mechanisms underlying the effect of gender on response to cardiac resynchronization therapy: insights from the SMART-AV multicenter trial. Heart Rhythm. 2012; 9: 736-741.
26. Stellbrink C, Breithardt OA, Franke A, et al. PATCH-CHF investigators. Impact of cardiac resynchronization therapy using hemodynamically optimized pacing on left ventricular remodeling in patients with congestive heart failure and ventricular conduction disturbances. J Am Coll Cardiol. 2001; 38: 1957-1965.
27. Bai R, Di Biase L, Elayi C, et al. Mortality of heart failure patients after cardiac resynchronization therapy: identification of predictors. J Cardiovasc Electrophysiol. 2008; 19: 1259-1265.
28. Kirubakaran S, Ladwiniec A, Arujuna A, et al. Male gender and chronic obstructive pulmonary disease predict a poor clinical response in patients undergoing cardiac resynchronisation therapy. Int J Clin Pract. 2011; 65: 281-288.
29. Solomon SD, Foster E, Bourgoun M, et al. Effect of cardiac resynchronization therapy on reverse remodeling and relation to outcome: Multicenter Automatic Defibrillator Implantation Trial: cardiac resynchronization therapy. Circulation. 2010; 122: 985-992.
30. Dickstein K, Bogale N, Priori S, et al. The European cardiac resynchronization therapy survey. Eur Heart J. 2009; 30: 2450-2460.
31. Tang AS, Wells GA, Talajic M, et al. Resynchronization-Defibrillation for Ambulatory Heart Failure Trial Investigators. Cardiac-resynchronization therapy for mild-to-moderate heart failure. N Engl J Med. 2010; 363: 2385-2395.
32. Celikyurt U, Agacdiken A, Sahin T, et al. Number of leads with fragmented QRS predicts response to cardiac resynchronization therapy. Clin Cardiol. 2013; 36: 36-39.